Last reviewed · How we verify
combination of high-dose rosuvastatin and ezetimibe
combination of high-dose rosuvastatin and ezetimibe is a Small molecule drug developed by Korea University Anam Hospital. It is currently FDA-approved.
At a glance
| Generic name | combination of high-dose rosuvastatin and ezetimibe |
|---|---|
| Sponsor | Korea University Anam Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events (PHASE3)
- Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis (PHASE2)
- Comparative Study of Rosuvastatin/Ezetimib 20/10 mg and Atovastatin/Ezetimib 40/10 mg (TOLERANT Trial) (PHASE4)
- Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization (PHASE4)
- Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque (PHASE4)
- Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention (PHASE4)
- Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial) (NA)
- Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- combination of high-dose rosuvastatin and ezetimibe CI brief — competitive landscape report
- combination of high-dose rosuvastatin and ezetimibe updates RSS · CI watch RSS
- Korea University Anam Hospital portfolio CI
Frequently asked questions about combination of high-dose rosuvastatin and ezetimibe
What is combination of high-dose rosuvastatin and ezetimibe?
combination of high-dose rosuvastatin and ezetimibe is a Small molecule drug developed by Korea University Anam Hospital.
Who makes combination of high-dose rosuvastatin and ezetimibe?
combination of high-dose rosuvastatin and ezetimibe is developed and marketed by Korea University Anam Hospital (see full Korea University Anam Hospital pipeline at /company/korea-university-anam-hospital).
What development phase is combination of high-dose rosuvastatin and ezetimibe in?
combination of high-dose rosuvastatin and ezetimibe is FDA-approved (marketed).